共 14 条
- [1] Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal CancerFRONTIERS IN ONCOLOGY, 2019, 9Oliveira, Andre F.Bretes, LuisFurtado, Irene
- [2] Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1726 - 1735Calles, AntonioLiao, XiaoyunSholl, Lynette M.Rodig, Scott J.Freeman, Gordon J.Butaney, MohitLydon, ChristineDahlberg, Suzanne E.Hodi, F. StephenOxnard, Geoffrey R.Jackman, David M.Jaenne, Pasi A.
- [3] Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)Fakih, MarwanSandhu, Jaideep SinghOuyang, ChingSokol, EthanRoss, Jeffrey S.Miller, Vincent A.Lim, DeanChao, JosephCatenacci, Daniel V. T.Cho, May ThetBraiteh, Fadi S.Maron, Steven BradChase, LeahKlempner, Samuel JacobAli, Siraj MahamedSchrock, Alexa Betzig
- [4] A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitorsIMMUNOLOGY, 2024, 173 (02) : 209 - 226Cai, LingliChen, AnqiTang, Dong
- [5] Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implicationsFRONTIERS IN PHARMACOLOGY, 2022, 13Guo, LibinTang, XiaoqiongWong, Sin WaGuo, AnyuanLin, YaoKwok, Hang Fai
- [6] Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T CellsCANCERS, 2020, 12 (11) : 1 - 22Baraibar, IosuneRoman, MartaRodriguez-Remirez, MariaLopez, InesVilalta, AnnaGuruceaga, ElisabethEcay, MargaritaCollantes, MariaLozano, TeresaAlignani, DiegoPuyalto, AnderOliver, AnaOrtiz-Espinosa, SergioMoreno, HaritzTorregrosa, MariaRolfo, ChristianCaglevic, ChristianGarcia-Ros, DavidVillalba-Esparza, MariaDe Andrea, CarlosVicent, SilvestrePio, RubenLasarte, Juan JoseCalvo, AlfonsoAjona, DanielGil-Bazo, Ignacio
- [7] PD-L1 Expression in IBD-Associated Colorectal Cancer and Its Relationship to MSI Status, the PI3K Pathway, and HLA-DR ExpressionLABORATORY INVESTIGATION, 2017, 97 : 158A - 158AAlpert, LindsayYassan, LindsayWeber, ChristopherXiao, Shu-YuanHart, JohnKrausz, ThomasSegal, JeremySetia, Namrata
- [8] PD-L1 Expression in IBD-Associated Colorectal Cancer and Its Relationship to MSI Status, the PI3K Pathway, and HLA-DR ExpressionMODERN PATHOLOGY, 2017, 30 : 158A - 158AAlpert, LindsayYassan, LindsayWeber, ChristopherXiao, Shu-YuanHart, JohnKrausz, ThomasSegal, JeremySetia, Namrata
- [9] The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapyCANCER MEDICINE, 2024, 13 (03):Liu, FangfangZhang, XuemeiLu, MengyaoLiu, ChunZhang, XiaodongChu, QianChen, YuanZhang, Peng
- [10] Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142ANNALS OF ONCOLOGY, 2017, 28Andre, T.Overman, M.Lonardi, S.Aglietta, M.McDermott, R.Wong, K. Y. M.Morse, M.Hendlisz, A.Moss, R. A.Ledeine, J-M.Tang, H.Cao, Z. A.Kopetz, S.